Navigation Links
MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has served Atomic Energy of Canada Limited (AECL) with notice of arbitration proceedings. MDS will be seeking an order to compel AECL to fulfill its contractual obligations under its 2006 interim and long-term supply agreement (ILTSA) and if not granted, seeking significant monetary damages. MDS has concurrently filed a court claim for $1.6 billion in damages against AECL, for negligence and breach of contract, and against the Government of Canada, for inducing breach of contract and for interference with economic relations.

"We have had to resort to taking these steps to protect the interests of patients, the nuclear medicine community, our shareholders and our customers," said Stephen P. DeFalco, President and CEO, MDS Inc. "We are disappointed that AECL and the Government decided to abandon the MAPLE project without establishing a clear plan for the long-term supply of critical medical isotopes."

MDS's primary objective through the legal proceedings is to have AECL honour its long standing commitment to replace the National Research Universal (NRU) reactor by bringing the MAPLE reactors into service, and provide a 40-year supply of medical isotopes, required by patients worldwide for serious medical needs.

In 1996, MDS entered into an agreement with AECL for the design, development and construction of two new nuclear reactors and a processing facility, known as the MAPLE project. The project was intended to replace AECL's NRU reactor, which produces approximately 50 per cent of the world's medical isotopes. AECL agreed to provide interim supply of medical isotopes from NRU until the MAPLE project was operational. The MAPLE project was to be completed by the year 2000 at a planned cost to MDS of $145 million.

By 2005, the project was not yet completed and
'/>"/>

SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
2. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
3. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
4. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
5. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
6. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. Cytopia Commences Phase II Cancer Drug Study
9. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
10. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
11. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 As reported by the Statesman Journal ... Heroin (7/20), police in Salem, MA as well as ... the recent heroin epidemic that has taken many lives during ... heroin-related overdose case in which police were able to make ... phone. By pretending to be the victim and claiming to ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
(Date:7/25/2014)... Hospital and MOSI officially announced a transformational partnership that will ... make a difference in the Tampa Bay community. Florida Hospital ... the support needed to keep the science center moving forward. ... Dome Theatre from film to a state-of-the-art digital 3D projection ... the state of Florida, and it is one of the ...
(Date:7/25/2014)... 25, 2014 Art of Facial Surgery has ... those in Toronto who are looking for minor touch-ups to ... done by the American Academy of Facial Plastic and Reconstructive ... in facial plastic surgery showed a surprising increase between 2012 ... percent, while hair transplants increased by 7 percent and eyelid ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 ... , a Nuanced Media client and the nation’s ... and dental employee handbooks, announced their partnership with ... TransAct is a registered ISO/MSP of Chase Paymentech ... the transaction processing industry. Companies that are members ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2
... The following is a,statement of Matthew L. Myers President, ... Two new reports released today by the U.S. ... adult smoking rate in the United States,has declined to ... rates are,not declining fast enough to reduce tobacco,s growing ...
... presidential candidate John Edwards and breast cancer ... of preserving in tough times, FERNDALE, Mich., Nov. 13 ... finding hope and inspiration in,life,s challenges to the Troy Hilton, ... Company and Metro Parent Magazine are proud to,present this unique ...
... one day lead to vaccine that works , , THURSDAY, Nov. ... AIDS vaccine has failed, but researchers report that they,ve still ... effective. , "It,s raised a whole new set of questions ... get us to a successful vaccine," said Dr. Susan P. ...
... Diluted Share, FARMINGDALE, N.Y., Nov. 13 Misonix, ... ultrasonic medical device,technology, which in Europe is used for ... conditions, today reported financial,results for its fiscal year 2009 ... President and Chief Executive Officer, and Richard,Zaremba, Senior VP ...
... In the December issue of European Urology ... associates report on the evidence of a relationship ... (LUTS) in men enrolled in the REDUCE trial. ... Cancer Events) trial is a 4-year, phase-III placebo-controlled ...
... Northridge Hospital Medical,Center (Northridge) credits TeleHealth Services, ... the organization,s recent awards and top,accreditation, all ... comfort as its medical experts provide superior ... acute care facility located in Northridge, CA,Northridge ...
Cached Medicine News:Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 2Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 3Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 4Health News:Elizabeth Edwards Reschedules Metro Detroit Appearance 2Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 2Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 3Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 4Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 5Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 6Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 7Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 8Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 9Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
(Date:7/24/2014)... July 24, 2014 IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, today announced it has ... of Directors.  Mr. Finio has accepted a senior level ... terms of his acceptance of his new position, Mr. ... as Director for IGI Laboratories, Inc.  The effective date ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... , , , , ... Inc. (Nasdaq: RIGL ) today announced that in the ... had failed to respond to at least one biologic treatment, the ... ACR 20, ACR 50, ACR 70 and DAS28 response rates than ...
... , G rowth ... for cardiac stem cells , ... regrow, but researchers at Children,s Hospital Boston have now laid the groundwork for ... in children with congenital heart defects. In the July 24 issue of ...
Cached Medicine Technology:R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 8Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3